Accès à distance ? S'identifier sur le proxy UCLouvain
Dose-escalation study using up to twice the standard dose of cetuximab in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST study): Preliminary data.
Primary tabs
| Document type | Communication à un colloque (Conference Paper) – Abstract, Présentation orale avec comité de sélection |
|---|---|
| Publication date | 2006 |
| Language | Anglais |
| Conference | "42nd Annual Meeting of the American-Society-of-Clinical-Oncology", Atlanta (Ga) (Jun 02-06, 2006) |
| Journal information | "Journal of Clinical Oncology" - Vol. 24, no. 18, p. 159S-159S (2006) |
| Peer reviewed | yes |
| issn | 0732-183X |
| e-issn | 1527-7755 |
| Publisher | Amer Soc Clinical Oncology (Alexandria) |
| Affiliations |
UCL
- Cliniques universitaires Saint-Luc UCL - MD/MINT - Département de médecine interne UCL - AGRO/CABI - Département de chimie appliquée et des bio-industries |
| Links |
| Bibliographic reference | Tejpar, Sabine ; Humblet, Yves ; Peeters, Marie-Rose ; Gelderblom, H. ; Vermorken, J. ; et. al. Dose-escalation study using up to twice the standard dose of cetuximab in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST study): Preliminary data..42nd Annual Meeting of the American-Society-of-Clinical-Oncology (Atlanta (Ga), Jun 02-06, 2006). In: Journal of Clinical Oncology, Vol. 24, no. 18, p. 159S-159S (2006) |
|---|---|
| Permanent URL | http://hdl.handle.net/2078.1/59894 |